Chemotherapy

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

Bevacizumab Efficacious for HER2-Negative Breast Cancer

January 25, 2012

Two studies show improved pathologic complete response with addition of bevacizumab.
 

Therapeutic vaccine for brain cancer being studied

January 24, 2012

A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Stem cell treatment does not improve overall survival in follicular lymphoma

Delicia Honen Yard January 12, 2012

High-dose chemotherapy combined with autologous stem cell transplantation did not improve overall survival in previously untreated adult patients with follicular lymphoma.
 

Study demonstrates mortality disparity among colorectal cancer patients

Delicia Honen Yard January 11, 2012

Concerted efforts to prevent or detect colorectal cancer at earlier stages in black patients could improve the worsening black-white disparities uncovered in a recent analysis.
 

New Predictors of Treatment Response Identified for CRC

January 04, 2012

Hypermethylation of TFAP2E associated with chemoresistance in colorectal cancer
 

Addition of vorinostat yields high remission rate in AML study

Delicia Honen Yard December 28, 2011

An 85% remission rate was noted in a group of patients with acute myeloid leukemia who received the histone deacetylase inhibitor vorinostat in addition to cytarabine and idarubicin.
 

Genetic variation in ovarian cancer thwarts treatment

Delicia Honen Yard December 27, 2011

Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
 
Visit Reflections for first-hand stories on the power of the patient to impact caregivers in oncology nursing.
Like to share a comment on our new site or another topic of interest to you? Click here and start typing.
ONA Newsletters
Sign up today for one of our free newsletters:
  • Issue Preview
  • Latest CE
  • Reflections
  • Editor's choice
  • New on the Web

Let us know what you are looking for in a new oncology nursing journal:

Click here to take our survey


Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions